Preexisting antibody assays for gene therapy : Considerations on patient selection cutoffs and companion diagnostic requirements
© 2024 The Author(s)..
Recombinant adeno-associated virus (AAV) vectors are the leading delivery vehicle used for in vivo gene therapies. Anti-AAV antibodies (AAV Abs) can interact with the viral capsid component of an AAV-based gene therapy (GT). Therefore, patients with preexisting AAV Abs (seropositive patients) are often excluded from GT trials to prevent treatment of patients who are unlikely to benefit1 or may have a higher risk for adverse events outweighing treatment benefits. On the contrary, unnecessary exclusion of patients with high unmet medical need should be avoided. Instead, a risk-benefit assessment that weighs the potential risks due to seropositivity vs. severity of disease and available treatment options, should drive the decision if patient selection is required. Assays for patient selection must be validated according to their intended use following national regulations/standards for diagnostic assays in appropriate laboratories. In this review, we summarize the current process of patient selection, including assay cutoff criteria and related assay validation approaches. We further provide considerations on regulatory requirements for the development of in vitro diagnostic tests supporting market authorization of a corresponding GT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Molecular therapy. Methods & clinical development - 32(2024), 1 vom: 14. März, Seite 101217 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Braun, Manuela [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 19.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.omtm.2024.101217 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369859952 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369859952 | ||
| 003 | DE-627 | ||
| 005 | 20240319233255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.omtm.2024.101217 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM369859952 | ||
| 035 | |a (NLM)38496304 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Braun, Manuela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preexisting antibody assays for gene therapy |b Considerations on patient selection cutoffs and companion diagnostic requirements |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Author(s). | ||
| 520 | |a Recombinant adeno-associated virus (AAV) vectors are the leading delivery vehicle used for in vivo gene therapies. Anti-AAV antibodies (AAV Abs) can interact with the viral capsid component of an AAV-based gene therapy (GT). Therefore, patients with preexisting AAV Abs (seropositive patients) are often excluded from GT trials to prevent treatment of patients who are unlikely to benefit1 or may have a higher risk for adverse events outweighing treatment benefits. On the contrary, unnecessary exclusion of patients with high unmet medical need should be avoided. Instead, a risk-benefit assessment that weighs the potential risks due to seropositivity vs. severity of disease and available treatment options, should drive the decision if patient selection is required. Assays for patient selection must be validated according to their intended use following national regulations/standards for diagnostic assays in appropriate laboratories. In this review, we summarize the current process of patient selection, including assay cutoff criteria and related assay validation approaches. We further provide considerations on regulatory requirements for the development of in vitro diagnostic tests supporting market authorization of a corresponding GT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a adeno-associated virus | |
| 650 | 4 | |a clinical decision limit | |
| 650 | 4 | |a companion diagnostic | |
| 650 | 4 | |a diagnostic assay strategy | |
| 650 | 4 | |a gene therapy | |
| 650 | 4 | |a in vitro diagnostic regulations | |
| 650 | 4 | |a patient selection | |
| 650 | 4 | |a preexisting antibodies | |
| 650 | 4 | |a reference limit | |
| 650 | 4 | |a risk-benefit assessment | |
| 700 | 1 | |a Lange, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Schatz, Philipp |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Stanta, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Gorovits, Boris |e verfasserin |4 aut | |
| 700 | 1 | |a Tarcsa, Edit |e verfasserin |4 aut | |
| 700 | 1 | |a Jawa, Vibha |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Tong-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lembke, Wibke |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a McBlane, Fraser |e verfasserin |4 aut | |
| 700 | 1 | |a Christodoulou, Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Yuill, Daisy |e verfasserin |4 aut | |
| 700 | 1 | |a Milton, Mark |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular therapy. Methods & clinical development |d 2014 |g 32(2024), 1 vom: 14. März, Seite 101217 |w (DE-627)NLM23764147X |x 2329-0501 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2024 |g number:1 |g day:14 |g month:03 |g pages:101217 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.omtm.2024.101217 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2024 |e 1 |b 14 |c 03 |h 101217 | ||